Categories: News

Conference Call on Interim Report

GOTHENBURG, SE / ACCESSWIRE / October 7, 2021 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)

Invitation to attend XVIVO’s conference call regarding the presentation of the interim report July – September 2021. The presentation will be held in English.

Time: Thursday, October 21, 2021 at 2.00 p.m. CET
Information regarding the conference can be found under the following link:
https://onlinexperiences.com/Launch/QReg/ShowUUID=07001B8B-3391-4BA9-8F3E-BBE54EDF834E .

Phone numbers to the conference:
Sweden: +46 856642651 PIN: 13466713#
UK: +44 3333000804 PIN: 13466713#
US: +1 6319131422 PIN: 13466713#
Conference name: XVIVO Group Interim Report Q3, conference ID: EV00128347

Participants from XVIVO:
Dag Andersson, CEO
Kristoffer Nordström, CFO

The press release for XVIVO’s interim report July-September 2021 will be released on October 21, 2021 at 7:30 a.m. CET.

Before the conference call, slides will be available at the company web page, https://www.xvivoperfusion.com/corporate/financial-presentations/earnings-calls/

October 7, 2021
Gothenburg
XVIVO Perfusion AB (publ)

For further information, please contact:

Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

Attachments

Conference call on Interim Report

SOURCE: XVIVO Perfusion AB

View source version on accesswire.com:
https://www.accesswire.com/667197/Conference-Call-on-Interim-Report

Staff

Recent Posts

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

1 hour ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

1 hour ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

1 hour ago

Calm Nature CBD Gummies Ingredients: 2026 Consumer Analysis Examines Full Spectrum CBD Claims, Testing Standards, and Formulation Transparency

Independent report examines Calm Nature CBD Gummies full spectrum formulation, CO2 extraction claims, THC removal…

2 hours ago